Trial Search Results

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has not responded to hormone therapy and has spread to other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors accurately measure how well patients respond to treatment with radium Ra 223 dichloride.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Procedure: Contrast-enhanced Magnetic Resonance Imaging
  • Drug: Fludeoxyglucose F-18
  • Drug: Fluorine F 18 Sodium Fluoride
  • Procedure: Magnetic Resonance Imaging
  • Procedure: Positron Emission Tomography

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Provides written informed consent

   - Diagnosed with mCRPC and painful bone metastases, referred for Xofigo (radium Ra 223
   dichloride)

   - Able to remain still for duration of the imaging procedure (about one hour)

Exclusion Criteria:

   - Metallic implants

Ages Eligible for Study

19 Years - N/A

Genders Eligible for Study

Male

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Omar Rutledge
650-721-4089
Recruiting